Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Monday, April 20, 2015

New T cell-based immunotherapy shows promise for lethal stem cell transplant complication

More than 60 percent of patients with Epstein-Barr virus-associated lymphoproliferative disorder that was not responding to standard rituximab treatment responded to a new type of immunotherapy called Epstein-Barr virus-specific cytotoxic T lymphocyte therapy, according to data from two clinical trials presented at here the AACR Annual Meeting 2015, April 18-22. "One of the most concerning complications of blood stem cell transplantation, which has transformed the lives of many patients , including those with leukemia and lymphoma, is EBV-LPD," said Richard J. O'Reilly, MD, chairman of the Department of Pediatrics and chief of the Pediatric Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York.
http://ift.tt/1OxUECC

No comments:

Post a Comment

Popular Stem Cell Roundup Posts